Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 61 to 75 of 160 results for asthma

  1. Dupilumab for treating severe chronic rhinosinusitis with nasal polyposis (Review of TA648) [ID6480]

    In development [GID-TA11630] Expected publication date: 11 September 2025

    Technology appraisal guidance
    In development

  2. Decreasing pharmacological treatment:- In adults, young people and children with well-controlled asthma, what are the objective measurements and prognostic factors that indicate that a decrease in regular maintenance treatment is appropriate?

    pharmacological treatment:- In adults, young people and children with well-controlled asthma, what are the objective measurements and...

    Research recommendation
    Published
    18 October 2018

  3. Environmental sustainability

    NICE is committed to supporting the national agenda for achieving a sustainable health and care system.

  4. Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (MA review of TA823) [ID6324]

    In development [GID-TA11616] Expected publication date: 23 July 2025

    Technology appraisal guidance
    In development

  5. Smoking: smoking status for people with long-term conditions (IND97)

    This indicator covers the percentage of patients with any or any combination of the following conditions: CHD, PAD, stroke or TIA, hypertension, diabetes, COPD, CKD, asthma, schizophrenia, bipolar affective disorder or other psychoses whose notes record smoking status in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM38

    General practice indicators suitable for use in QOF
    Last updated
    5 April 2022

  6. Pneumonia in adults: diagnosis and management (CG191)

    This guideline was developed before the COVID-19 pandemic. It covers diagnosing and managing pneumonia in adults who do not have COVID-19. It aims to improve accurate assessment and diagnosis of pneumonia to help guide antibiotic prescribing and ensure that people receive the right treatment.

    Clinical guideline
    Last updated
    31 October 2023
    View recommendations

    Sections for CG191

  7. Depemokimab for treating severe eosinophilic asthma in people 12 years and over ID6447

    Awaiting development [GID-TA11553] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. NICE discussed the potential for future research. NICE accepted that there is a need to further establish the accuracy of current practice in diagnosing asthma and the incremental accuracy associated with the addition of FeNO testing.

    need to further establish the accuracy of current practice in diagnosing asthma and the incremental accuracy associated with the...

    Research recommendation
    Published
    9 June 2015

  9. Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma [ID4044]

    In development [GID-TA10930] Expected publication date: 28 May 2025

    Technology appraisal guidance
    In development

  10. Durvalumab for treating limited-stage small-cell lung cancer after chemoradiation ID5073

    In development [GID-TA10959] Expected publication date: 23 July 2025

    Technology appraisal guidance
    In development

  11. Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer ID6256

    In development [GID-TA11279] Expected publication date: 20 August 2025

    Technology appraisal guidance
    In development

  12. Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis ID6266

    In development [GID-TA11248] Expected publication date: 16 July 2025

    Technology appraisal guidance
    In development

  13. Datopotamab deruxtecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6241]

    In development [GID-TA11277] Expected publication date: 13 August 2025

    Technology appraisal guidance
    In development

  14. Physical health of people in prison (NG57)

    This guideline covers assessing, diagnosing and managing physical health problems of people in prison. It aims to improve health and wellbeing in the prison population by promoting more coordinated care and more effective approaches to prescribing, dispensing and supervising medicines.

    NICE guideline
    Published
    2 November 2016
    View recommendations

    Sections for NG57

  15. Osimertinib for maintenance treatment of EGFR mutation-positive locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation [ID6223]

    In development [GID-TA11232] Expected publication date: 20 August 2025

    Technology appraisal guidance
    In development